Working... Menu
Trial record 1 of 1 for:    2215-CL-0301: NCT02421939
Previous Study | Return to List | Next Study

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02421939
Recruitment Status : Active, not recruiting
First Posted : April 21, 2015
Last Update Posted : May 24, 2019
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. )

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Actual Primary Completion Date : September 17, 2018
  Estimated Study Completion Date : December 2020